David Raben, Chief Medical Officer of Bicara Therapeutics Inc. ($BCAX), made six open market sales of common shares in the last year, totaling about $917,000. His most recent sale occurred on March 4, 2026. These transactions rank him 5,127th among 11,678 insiders by sale value, well below the average of $8.6 million across roughly six sales per insider. Raben made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 5500 | $3.79 | 60,786.0000 | 54,563,864 | 9.95% | 0.01% |
| March 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 5500 | $0.00 | 47,413.0000 | 54,563,864 | 10.39% | 0.01% |
| March 25, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 5500 | $18.95 | 55,286.0000 | 54,563,864 | 9.05% | 0.01% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 16300 | $18.52 | 55,286.0000 | 54,563,864 | 22.77% | 0.03% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 16300 | $3.79 | 71,586.0000 | 54,563,864 | 29.48% | 0.03% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 200 | $3.79 | 55,486.0000 | 54,563,864 | 0.36% | 0.00% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 200 | $18.45 | 55,286.0000 | 54,563,864 | 0.36% | 0.00% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 16300 | $0.00 | 52,913.0000 | 54,563,864 | 23.55% | 0.03% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 200 | $0.00 | 69,213.0000 | 54,563,864 | 0.29% | 0.00% |
| Feb. 2, 2026 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 54,563,864 | 9999.99% | 0.18% |
| Dec. 26, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 19789 | $3.79 | 55,286.0000 | 54,563,864 | 55.75% | 0.04% |
| Dec. 26, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 19789 | $0.00 | 98,987.0000 | 54,563,864 | 16.66% | 0.04% |
| Nov. 25, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 906 | $0.00 | 69,413.0000 | 54,563,864 | 1.29% | 0.00% |
| Nov. 25, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 4594 | $3.79 | 40,091.0000 | 54,563,864 | 12.94% | 0.01% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 5500 | $18.45 | 35,497.0000 | 54,563,864 | 13.42% | 0.01% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 5500 | $3.79 | 40,997.0000 | 54,563,864 | 15.49% | 0.01% |
| Nov. 25, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 4594 | $0.00 | 118,776.0000 | 54,563,864 | 3.72% | 0.01% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 5500 | $0.00 | 123,370.0000 | 54,563,864 | 4.27% | 0.01% |
| Nov. 25, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 906 | $18.84 | 35,497.0000 | 54,563,864 | 2.49% | 0.00% |
| Nov. 25, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 906 | $3.79 | 36,403.0000 | 54,563,864 | 2.55% | 0.00% |
| Nov. 25, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 4594 | $18.84 | 35,497.0000 | 54,563,864 | 11.46% | 0.01% |
| Oct. 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | S | Common Stock | 22000 | $18.45 | 35,497.0000 | 54,563,864 | 38.26% | 0.04% |
| Oct. 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Stock Option (Right to Buy) | 22000 | $0.00 | 128,870.0000 | 54,563,864 | 14.58% | 0.04% |
| Oct. 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Raben David | Chief Medical Officer | M | Common Stock | 22000 | $3.79 | 57,497.0000 | 54,563,864 | 61.98% | 0.04% |